Literature DB >> 3529321

Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria.

E Tuomanen.   

Abstract

beta-Lactam antibiotics rapidly kill bacteria during logarithmic growth but fail to kill nongrowing cells. This trait is the most universal example of phenotypic tolerance (the ability of bacteria to evade the bactericidal activity of antibiotics). Both nongrowing and slowly growing bacteria are found very frequently during infection in vivo, and phenotypic tolerance to the bactericidal activity of antibiotics as a consequence of reduced growth rate can be detected in vivo. With the use of an in vitro model system of nongrowing bacteria, a select group of beta-lactam antibiotics has been found that demonstrates a striking and unusual ability to kill nongrowing bacteria despite phenotypic tolerance to conventional beta-lactam antibiotics. These same compounds also effectively kill phenotypically tolerant cells in cerebrospinal fluid and serum. The extension of bactericidal activity to nongrowing and slowly growing bacteria may be a major advance in efforts to improve the chemotherapy for infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529321     DOI: 10.1093/clinids/8.supplement_3.s279

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  62 in total

1.  In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.

Authors:  K Hamamoto; T Shimizu; N Fujimoto; Y Zhang; S Arai
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Persistent bacteremia in rabbit fetuses despite maternal antibiotic therapy in a novel intrauterine-infection model.

Authors:  C Gras-Le Guen; T Debillon; C Toquet; A Jarry; N Winer; C Jacqueline; M F Kergueris; E Bingen; J C Roze; G Potel; D Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 3.  Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy.

Authors:  H Anwar; J L Strap; J W Costerton
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 4.  Remarks on the screening of antibiotics for antibacterial activity.

Authors:  O Zak; H Mett; T O'Reilly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

5.  A novel mechanism of growth phase-dependent tolerance to isoniazid in mycobacteria.

Authors:  Makoto Niki; Mamiko Niki; Yoshitaka Tateishi; Yuriko Ozeki; Teruo Kirikae; Astrid Lewin; Yusuke Inoue; Makoto Matsumoto; John L Dahl; Hisashi Ogura; Kazuo Kobayashi; Sohkichi Matsumoto
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

6.  Oxacillin, cephalothin, and vancomycin tube macrodilution MBC result reproducibility and equivalence to MIC results for methicillin-susceptible and reputedly tolerant Staphylococcus aureus isolates.

Authors:  L L Pelletier; C B Baker
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

7.  Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms.

Authors:  P Moreillon; Z Markiewicz; S Nachman; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

8.  Protective effects of local administration of ciprofloxacin on the risk of pneumococcal meningitis after cochlear implantation.

Authors:  Benjamin P C Wei; Roy M Robins-Browne; Robert K Shepherd; Kristy Azzopardi; Graeme M Clark; Stephen J O'Leary
Journal:  Laryngoscope       Date:  2006-12       Impact factor: 3.325

9.  Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors:  J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.